Conferences - Results from #9640

SUFU Winter Meeting 2013 - Percutaneous tibial nerve stimulation for the treatment of overactive bladder syndrome: Final 36-month results of the STEP study - Poster March 13, 2013

SUFU Winter Meeting 2013 - Clinical insights into percutaneous tibial nerve stimulation (PTNS) vs. sham therapy for the treatment of overactive bladder syndrome (OAB): Secondary analysis of the SUmiT trial - Poster March 13, 2013

SUFU Winter Meeting 2013 - Neurostimulation treatment for overactive bladder (OAB): An evaluation of cost effectiveness data - Session Highlights March 12, 2013

SUFU Winter Meeting 2013 - Overview of AUA/SUFU overactive bladder guidelines - Session Highlights March 8, 2013

SUFU Winter Meeting 2013 - Overview of AUA/SUFU urodynamics guidelines - Session Highlights March 7, 2013

GU Cancers Symposium 2013 - Evolving patterns of metastatic disease in castration resistant prostate cancer reported in clinical trials from 1990 to 2011, by William K. Oh, MD, et al. - Session Highlights February 28, 2013

GU Cancers Symposium 2013 - Poster: Evolving patterns of metastatic disease in castration resistant prostate cancer reported in clinical trials from 1990 to 2011, by William K. Oh, MD, et al. February 28, 2013

GU Cancers Symposium 2013 - Poster: Bone health among prostate cancer survivors: Long term follow-up from the prostate cancer outcomes study (PCOS), by Alicia Morgans, MD, et al February 26, 2013

GU Cancers Symposium 2013 - Session Highlights: Overall survival and safety of dasatinib/docetaxel vs docetaxel in patients with metastatic castration-resistant prostate cancer: Results from the randomized phase 3 READY trial, by John C. Araujo, MD, PhD February 26, 2013

GU Cancers Symposium 2013 - Overall survival and safety of dasatinib/docetaxel vs docetaxel in patients with metastatic castration-resistant prostate cancer: Results from the randomized phase 3 READY trial, by John C. Araujo, MD, PhD, et al. - Poster February 26, 2013

GU Cancers Symposium 2013 - Lower risk of cardiovascular events and death in patients treated with degarelix compared with LHRH agonists, by Peter Albertsen, MD, et al. - Poster February 26, 2013

GU Cancers Symposium 2013 - Degarelix versus LHRH agonists: Differential skeletal and urinary tract outcomes from an analysis of six comparative randomized clinical trials, by E. David Crawford, MD et al. - Poster February 26, 2013

GU Cancers Symposium 2013 - Galeterone, abiraterone, orteronel and ketoconazole exhibit differential inhibitory effects on CYP17 and steroidogenesis, by Douglas B. Jacoby and Martin Williams - Poster February 26, 2013

GU Cancers Symposium 2013 - A randomized, phase II, open-label study of sipuleucel-t with concurrent or sequential abiraterone acetate in metastatic castrate-resistant prostate cancer, by Eric J. Small, MD, et al. - Poster February 26, 2013

GU Cancers Symposium 2013 - Differential effects of galeterone, abiraterone, orteronel, and ketoconazole on CYP17 and steroidogenesis, by Douglas B. Jacoby, et al. - Session Highlights February 26, 2013

GU Cancers Symposium 2013 - A randomized phase II, open-label study of sipuleucel-T with concurrent or sequential abiraterone acetate in metastatic castrate-resistant prostate cancer - Session Highlights February 26, 2013

GU Cancers Symposium 2013 - Effect of PSA-TRICOM, a pox-viral vaccine in prostate cancer (PCa), on tumor growth rates within 80 days after initiation in nonmetastatic PCa, by James L. Gulley, et al. - Session Highlights February 25, 2013

GU Cancers Symposium 2013 - The initial biopsy Gleason score as a predictive marker for docetaxel survival benefit in patients with prostate cancer: Data from the TAX 327 study, by Robert van Soest, et al. - Session Highlights February 25, 2013

GU Cancers Symposium 2013 - Characterization of patients who present with de novo metastatic prostate cancer: Single-institution database analysis, by Jessica Strock, et al. - Session Highlights February 25, 2013

GU Cancers Symposium 2013 - Enzalutamide monotherapy: Phase II study results in patients with hormone-naive prostate cancer, by Bertrand Tombal, MD, PhD, et al. - Session Highlights February 25, 2013

Page 483 of 507